Catalina Capital Group LLC Makes New $323,000 Investment in Gilead Sciences, Inc. (NASDAQ:GILD)

Catalina Capital Group LLC bought a new position in Gilead Sciences, Inc. (NASDAQ:GILD) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 3,857 shares of the biopharmaceutical company’s stock, valued at approximately $323,000.

Other institutional investors also recently modified their holdings of the company. Manning & Napier Advisors LLC bought a new position in shares of Gilead Sciences in the second quarter worth about $25,328,000. Legal & General Group Plc grew its position in shares of Gilead Sciences by 0.8% during the 2nd quarter. Legal & General Group Plc now owns 12,414,268 shares of the biopharmaceutical company’s stock worth $851,743,000 after buying an additional 93,068 shares during the period. IRON Financial LLC acquired a new stake in shares of Gilead Sciences during the 3rd quarter worth approximately $830,000. GSA Capital Partners LLP acquired a new stake in shares of Gilead Sciences during the 1st quarter worth approximately $462,000. Finally, Wealth Enhancement Advisory Services LLC grew its position in shares of Gilead Sciences by 13.1% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 286,116 shares of the biopharmaceutical company’s stock worth $19,630,000 after buying an additional 33,162 shares during the period. 83.67% of the stock is owned by institutional investors.

Gilead Sciences Price Performance

Shares of GILD opened at $91.69 on Thursday. The firm has a market capitalization of $114.15 billion, a PE ratio of 111.82, a PEG ratio of 3.13 and a beta of 0.17. The company’s 50-day moving average is $84.58 and its 200-day moving average is $74.67. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $91.98. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.14 and a quick ratio of 0.95.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, beating the consensus estimate of $1.61 by $0.40. The company had revenue of $6.95 billion for the quarter, compared to analyst estimates of $6.64 billion. Gilead Sciences had a net margin of 3.79% and a return on equity of 29.34%. Equities analysts forecast that Gilead Sciences, Inc. will post 3.75 EPS for the current year.

Insider Activity

In other news, insider Johanna Mercier sold 29,357 shares of the stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $83.78, for a total value of $2,459,529.46. Following the transaction, the insider now directly owns 78,127 shares of the company’s stock, valued at $6,545,480.06. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, insider Johanna Mercier sold 29,357 shares of the stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $83.78, for a total value of $2,459,529.46. Following the transaction, the insider now directly owns 78,127 shares of the company’s stock, valued at $6,545,480.06. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $83.83, for a total transaction of $167,660.00. Following the completion of the transaction, the insider now owns 100,189 shares in the company, valued at $8,398,843.87. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 36,847 shares of company stock valued at $3,033,340 over the last ninety days. 0.29% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several equities research analysts have recently commented on GILD shares. BMO Capital Markets lifted their price target on shares of Gilead Sciences from $85.00 to $94.00 and gave the stock an “outperform” rating in a research report on Thursday, October 17th. Cantor Fitzgerald reiterated a “neutral” rating and set a $70.00 price target on shares of Gilead Sciences in a research report on Monday, September 16th. Leerink Partnrs upgraded shares of Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 21st. Royal Bank of Canada reiterated a “sector perform” rating and set a $75.00 price target on shares of Gilead Sciences in a research report on Tuesday, October 29th. Finally, Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a report on Thursday, August 15th. Ten research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and three have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $86.85.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.